Key facts
- It has raised $20.0M; the latest was Angel (individual) ($20.0M) in Oct 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for AccufyDx
- ·The full record, as it builds
Funding rounds
No funding rounds for AccufyDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AccufyDx
Developer of multiomic NGS (Next-Generation Sequencing) technologies designed to enhance early cancer detection. The company offers proprietary tagging and enrichment technologies featuring ultra-sensitive ctDNA (Circulating Tumor Deoxyribonucleic Acid) detection, rapid sample preparation, and preservation of epigenetic and genetic data, enabling clinicians to detect minimal residual disease with accuracy and speed for improved patient outcomes.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2022
- Employees
- 7
- Website
- accufydx.com/
- Ownership
- Privately Held (backing)
AccufyDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AccufyDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AccufyDx in its N-PORT filings yet. We sweep new filings monthly.